Insulet Corp. Stock Hits 52-Week Low at USD 140.63

Insulet Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 140.63 as of May 28, 2026. This decline marks a significant downturn for the company, which has seen its stock price drop by 25.72% over the past year, contrasting sharply with the S&P 500's performance of 28.45% during the same period. Despite the recent price drop, Insulet Corp. has demonstrated healthy long-term growth metrics, with net sales increasing at an annual rate of 24.53% and operating profit soaring by 55.87%. The company reported strong operating cash flow of USD 619.3 million, alongside a notable inventory turnover ratio of 1.82 times. However, the stock's performance has been overshadowed by a return on capital employed (ROCE) of 11.86%, indicating lower profitability relative to total capital. Additionally, the company has experienced a significant decline in profits, down by 18.4% over the past year. With a market capitalization of USD 15,815 million, Insulet Corp. continues to navigate a challenging market landscape while maintaining high institutional holdings at 100%.